Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted.
The following resolutions were made:
Approval of the audited Annual Report for 2024Approval of distribution of profit with payment of an ordinary dividend of DKK 4.20 (corresponding to approximately EUR 0.56) per A and B share. In addition to this year-end dividend, an interim dividend of DKK 2.00 (EUR ~0.27) was disbursed on September 3, 2024.Approval of the Remuneration Report for 2024 (advisory vote)Approval of the remuneration of members of the Board of Directors for 2025Re-election of Cornelis (Cees) de Jong as Chair of the Board of DirectorsRe-election of Heine Dalsgaard as a member of the Board of Directors and election as new Vice Chair Re-election of Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton as members of the Board of Directors Election of Monila Kothari as a new member of the Board of DirectorsRe-election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reportingApproval to renew the authorizations to the Board of Directors to implement capital increases Approval to renew the authorization to the Board of Directors to acquire treasury sharesApproval of the authorization to the Board of Directors to distribute extraordinary dividends
Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.
The Board of Directors, including its committees, is now composed as follows:
Cees (Cornelis) de Jong (Chair of the Board, chair of the Nomination and Remuneration Committee and member of the Audit Committee)Heine Dalsgaard (Vice Chair of the Board and member of the Audit Committee)Robert Nøddeskov Jensen (employee representative) Lise Kaae (chair of the Audit Committee)Monila Kothari (member of the Innovation Committee)Kasim Kutay (member of the
